Skip to Main Content
Phase III

NIMBLE

  • Study HIC#:2000030951
  • Last Updated:08/11/2023

Non-inferiority study of GSK3511294 compared with mepolizumab or benralizumab in participants with severe asthma with an eosinophilic phenotype.

  • Age12 years and older
  • GenderBoth

Contact Us

For more information about this study, including how to volunteer, contact:

Katie Spaulding

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call +18779788343 for more information.

Trial Purpose and Description

Non-inferiority study of GSK3511294 compared with mepolizumab or benralizumab in participants with severe asthma with an eosinophilic phenotype.

Eligibility Criteria

Adults and adolescents ≥ 12 years) at the time of signing the informed consent.

Documented physician diagnosis of asthma for ≥ 2 years

Anti-Il-5/5R Therapy: Receiving either mepolizumab 100mg SC or benralizumab 30mg SC for ≥12 months prior to Screening and have a documented benefit to therapy asses by either:

  • Reduction in exacerbation frequency since initiating treatment
  • Reduction in maintenance OCS since initiating treatment

A well document requirement for regular treatment with medium to high dose ICS in the 12 months prior to Visit 1 with or without maintenance OCS.

Additional Controller Medication: Current treatment with at least one additional controller medication, besides ICS.

Female Participants: A female participant is eligible to participate if she is not pregnant or breastfeeding, and one of the following conditions applies:

  • Is a woman of non-childbearing potential
  • Is a woman of childbearing potential and using a contraceptive method that is highly effective, with a failure rate of <1% from at least 14 days prior to the first dose of study intervention until at least 30 weeks after either the first dose or the dose at Week 26

Principal Investigator

For more information about this study, including how to volunteer, contact: